HDAC inhibitor quisinostat in synovial sarcoma cell lines
An RNA Seq study of the effects of HDAC inhibitor Quisinostat on six different synovial sarcoma cell lines
- 28/11/2017
- 12 samples
- DAC: EGAC00000000011
- Technology: NextSeq 500
- RS DUO:0000012 (version: 2021-02-23)research specific restrictionsThis data use modifier indicates that use is limited to studies of a certain research type.
- TS DUO:0000025 (version: 2021-02-23)time limit on useThis data use modifier indicates that use is approved for a specific number of months.
BC Cancer, part of the Provincial Health Services Authority - Data Access Policy
Access to this data is controlled. There are a number of steps that a researcher must take to obtain access to this data, including execution of a Data Access Agreement between the institutions. The process is overseen by the Technology Development Office; please contact our general email address TDOadmin@phsa.ca. Please only click the "request data" button on the EGA website after a Data Access Agreement is fully executed.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001002637 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.